TNFSF11/RANKL Polyclonal antibody
TNFSF11/RANKL Polyclonal Antibody for WB, IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (2)
Applications
WB, IHC, IF, ELISA, Cell treatment
Conjugate
Unconjugated
Cat no : 23408-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | Raji cells |
Positive IHC detected in | human stomach cancer tissue, human colon tissue, human heart tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:1000 |
Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
WB | See 38 publications below |
IHC | See 23 publications below |
IF | See 6 publications below |
Product Information
23408-1-AP targets TNFSF11/RANKL in WB, IHC, IF, ELISA, Cell treatment applications and shows reactivity with human samples.
Tested Reactivity | human |
Cited Reactivity | human, mouse, rat |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | TNFSF11/RANKL fusion protein Ag19975 |
Full Name | tumor necrosis factor (ligand) superfamily, member 11 |
Calculated Molecular Weight | 317 aa, 35 kDa |
Observed Molecular Weight | 30 kDa |
GenBank Accession Number | BC074890 |
Gene Symbol | RANKL |
Gene ID (NCBI) | 8600 |
RRID | AB_2879273 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
TNFSF11 also known as RANKL, is a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. RANKL is a polypeptide of 217 amino acids that exerts its biological activity both in a transmembrane form of about 40-45 kDa and in soluble one of 31 kDa (PMID: 15308315). The membrane-bound RANKL (mRANKL) is cleaved into a sRANKL by the metalloprotease-disintegrin TNF-alpha convertase (TACE) or a related metalloprotease (MP). RANKL induces osteoclast formation through its receptor, RANK, which transduces signals by recruiting adaptor molecules, such as the TNF receptor-associated factor (TRAF) family of proteins. RANKL was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. RANKL was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for TNFSF11/RANKL antibody 23408-1-AP | Download protocol |
IHC protocol for TNFSF11/RANKL antibody 23408-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
J Extracell Vesicles Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p. | ||
Aging Cell Pyrroloquinoline quinone alleviates natural aging-related osteoporosis via a novel MCM3-Keap1-Nrf2 axis-mediated stress response and Fbn1 upregulation | ||
J Control Release Sialic acid-modified chitosan oligosaccharide-based biphasic calcium phosphate promote synergetic bone formation in rheumatoid arthritis therapy. | ||
Aging (Albany NY) Increased expression of osteopontin in subchondral bone promotes bone turnover and remodeling, and accelerates the progression of OA in a mouse model. | ||
Int Immunopharmacol Clearance of senescent cells by navitoclax (ABT263) rejuvenates UHMWPE-induced osteolysis |